A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity of Splice Isoforms of Spinal Muscular Atrophy Genes by Singh, Natalia N. et al.
Biomedical Sciences Publications Biomedical Sciences
2012
A Multi-Exon-Skipping Detection Assay Reveals
Surprising Diversity of Splice Isoforms of Spinal
Muscular Atrophy Genes
Natalia N. Singh
Iowa State University, natalias@iastate.edu
Joonbae Seo
Iowa State University, jbseo@iastate.edu
Sarah Jane Rahn
Iowa State University, sjrahn@iastate.edu
Ravindra N. Singh
Iowa State University, singhr@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/bms_pubs
Part of the Genetic Processes Commons, Medical Biochemistry Commons, and the Medical
Genetics Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
bms_pubs/4. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Biomedical Sciences at Iowa State University Digital Repository. It has been accepted for
inclusion in Biomedical Sciences Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please
contact digirep@iastate.edu.
A Multi-Exon-Skipping Detection Assay Reveals Surprising Diversity of
Splice Isoforms of Spinal Muscular Atrophy Genes
Abstract
Humans have two near identical copies of Survival Motor Neuron gene: SMN1 and SMN2. Loss of SMN1
coupled with the predominant skipping of SMN2 exon 7 causes spinal muscular atrophy (SMA), a
neurodegenerative disease. SMA patient cells devoid of SMN1 provide a powerful system to examine splicing
pattern of various SMN2 exons. Until now, similar system to examine splicing of SMN1 exons was unavailable.
We have recently screened several patient cell lines derived from various diseases, including SMA, Alzheimer’s
disease, Parkinson’s disease and Batten disease. Here we report a Batten disease cell line that lacks functional
SMN2, as an ideal system to examine pre-mRNA splicing of SMN1. We employ a multiple-exon-skipping
detection assay (MESDA) to capture simultaneously skipping of multiple exons. Our results show surprising
diversity of splice isoforms and reveal novel splicing events that include skipping of exon 4 and co-skipping of
three adjacent exons of SMN. Contrary to the general belief, MESDA captured oxidative-stress induced
skipping of SMN1 exon 5 in several cell types, including non-neuronal cells. We further demonstrate that the
predominant SMN2 exon 7 skipping induced by oxidative stress is modulated by a combinatorial control that
includes promoter sequence, endogenous context, and the weak splice sites. We also show that an 8-mer
antisense oligonucleotide blocking a recently described GC-rich sequence prevents SMN2 exon 7 skipping
under the conditions of oxidative stress. Our findings bring new insight into splicing regulation of an essential
housekeeping gene linked to neurodegeneration and infant mortality.
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Introduction
Alternative pre-mRNA splicing increases the coding potential of
eukaryotic genome by producing multiple proteins from a single
gene [1]. As per current estimate, more than 95% of human genes
with two or more exons are alternatively spliced [2]. Splicing is
catalyzed by spliceosome, a macromolecular machine, which is
assembled de novo for the removal of each intron [3,4]. Splicing
is also coupled with transcription as several splicing factors are
recruited to spliceosome and/or pre-mRNA sequence through
RNA polymerase [5]. Regulation of alternative splicing rests on
non-spliceosomal factors that bind to pre-mRNA sequences called
exonic or intronic splicing enhancers (ESEs or ISEs) and silencers
(ESSs or ISSs) [6–8]. Enhancer and silencer motifs promote or
suppress splice-site (ss) selection, respectively. Due to the difference
in arrangement of cis-elements within exonic and flanking intronic
sequences, regulation of alternative splicing of each exon is unique
[9,10]. Mutations within regulatory sequences and/or aberrant
expression of splicing factors due to genotoxic and/or oxidative
stress (OS) result in defective splicing [11–17]. However, there are
very limited studies capturing OS-triggered aberrant splicing of
multiple exons in a single transcript of an essential human gene.
Also it is not known if deleterious effect of OS on splicing of a
specific exon could be prevented by strengthening of a ss.
Humans have two near identical copies of Survival Motor Neuron
gene: SMN1 and SMN2 [18]. Hereafter, SMN (in italics) refers to a
gene or a transcript, whereas SMN (in normal case capital letters)
refers to a protein. Both SMN genes code for identical proteins;
however, SMN2 predominantly generates a short transcript due to
skipping of exon 7, producing a truncated protein (SMND7) that is
highly unstable [19–21]. Therefore, SMN1 serves as the primary
gene for production of full-length SMN, a multifunctional protein
containing nucleic acid binding, tudor, Sm binding, Calpain
cleavage, ZPR1 binding and Gemin2 binding domains (Figure 1)
[22–28]. Interaction of SMN with Gemin2 is essential for the
formation of a large heteromeric complex (SMN complex) that
participates in snRNP biogenesis, an important housekeeping
function [29,30]. SMN is also implicated in transcription, DNA
recombination, signal transduction, stress granule formation,
vesicular transport and motor neuron trafficking [31–37]. The
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inability of SMN2 to compensate for the loss of SMN1 results in
spinal muscular atrophy (SMA), a leading genetic cause of infant
mortality [38]. The exact function of SMN2 remains unknown,
although, several lines of evidence support its role in cellular
metabolism. For instance, a SMA mouse model expressing very
high levels of SMND7 showed prolonged lifespan [39]. Further,
deletion of SMN2 has been associated with higher incidence of
amyotrophic lateral sclerosis (ALS) and lower motor neuron
disease [40,41]. In addition, SMN2 serves as a spare gene with a
potential to be corrected in SMA. Indeed, recent reports of
correction of SMN2 exon 7 splicing in animal models have shown
promise for SMA therapy [42–47]. Most lead compounds to show
therapeutic potential in animal models have been initially found to
correct SMN2 exon 7 splicing in cultured SMA patient cells. In
particular, publically available GM03813 cell line that lacks SMN1
has emerged as a cell-based model system for the preliminary
screening of potential SMA drugs [48–54]. GM03813 cell line has
also been useful in validating regulatory cis-elements and
transacting factors that modulate SMN2 exon 7 splicing [48,51–
55]. On the other hand, there is no systematic study on SMN1
splicing regulation in a publically available SMN2-lacking cell line.
Both SMN1 and SMN2 have similar gene organization i.e. nine
exons and eight introns (Figure 2A). A critical cytosine (C) to
thymidine (T) mutation at the 6th position (C6U transition in
transcript) of exon 7 and an adenosine (A) to guanosine (G)
transition at the 100th position (A100G) of intron 7 cause SMN2
exon 7 skipping [19,56]. Both, C6U and A100G mutations create
binding sites for an inhibitory protein hnRNP A1 that weakens the
39 ss of SMN2 exon 7 [56]. An additional G to A mutation at the
236th position (G236A) of non-coding exon 8 creates a SMN2-
specific signature motif (CTNAG) that could be cleaved by DdeI
restriction endonuclease (Figure 2A). Therefore, DdeI digestion
has been useful in distinguishing SMN2 transcripts from SMN1
transcripts [19]. Based on studies in SMA patient cells as well as in
mouse models carrying SMN2, skipping of SMN2 exons 3, 5 and 7
have been confirmed [18,48,53,57]. There is also evidence to
suggest very small but detectable skipping of SMN1 exon 5 and
exon 7 in certain cell types [18,19,58]. However, it is not known if
splicing of two or more exons of SMN is co-regulated. Also, there is
no report of skipping of SMN1 exon 3. In general, there is a lack of
a reliable assay to capture the relative abundance of the major
splice variants of SMN1 and SMN2.
Paraquat (PQ), an herbicide and oxidative stress (OS)-causing
agent, has been linked to the increased risks of neurological
disorders, including Parkinson’s disease [59]. Incidentally, PQ
treatment of neuronal cells have been shown to cause enhanced
skipping of exons 5 and 7 of SMN2 but not SMN1 [60]. Although
not independently validated, these findings put SMA patients into
the category of high-risk candidates who are likely to be affected
the most under the conditions of OS. In addition, OS-induced
enhanced skipping of SMN2 exon 7 raises the fundamental
question whether any of the strategies aimed at the correction of
SMN2 exon 7 splicing in SMA will retain its efficacy under the
conditions of OS. Given a high degree of sequence conservation
between SMN1 and SMN2, it is likely that some of the yet
uncharacterized splicing events in OS are common to both, SMN1
and SMN2. A definitive answer to this question awaits further
experimentation in specific cell types that express either SMN1 or
SMN2.
Here we report a systematic analysis of splice isoforms
generated by SMN1 and SMN2 under normal and OS conditions.
Our study also addresses an important question of neuronal versus
non-neuronal regulation of alternative splicing of various SMN
exons. One of the defining aspects of this study is the application of
a multiple-exon-skipping detection assay (MESDA) that captures
the relative abundance of all major splice variants of SMN. We also
take advantage of a unique cell type (GM20384) that we
serendipitously discovered to lack SMN2 transcripts probably
due to a partial or complete deletion of SMN2 alleles. Our findings
reveal novel splice variants, including those generated by an
unexpected skipping of exon 4 and/or several adjacent exons of
SMN. We show that OS affects alternative splicing of several exons
of SMN1 and SMN2 in both, neuronal and non-neuronal cells.
Our results suggest an OS-induced collaborative skipping of SMN2
exons 5 and 7. Further, we demonstrate that skipping of SMN2
exon 7 under OS is dependent upon several factors including
promoter sequence, endogenous context and the strength of ss. We
also demonstrate that an antisense oligonucleotide (ASO)-based
strategy to correct SMN2 exon 7 splicing retains its efficacy under
the conditions of OS.
Results
Identification of a Cell Line that Lacks SMN2
To explore the possibility that different pathological conditions
can affect splicing of SMN exon 7, we screened a number of
publically available patient cell lines, including batten disease (BD),
Parkinson’s disease and Alzheimer’s disease cell lines (Table 1,
Figure 2B). As a control, we also used undifferentiated neuronal
SH-SY5Y cells (lane 1, Figure 2B). SMN1/SMN2 transcripts were
analyzed by a sensitive radioactive RT-PCR using forward and
reverse primers annealing to exon 6 and exon 8, respectively.
Importantly, PCR products contained the SMN2-specific DdeI
restriction site within exon 8 (Figure 2A). Therefore, after DdeI
digestion of PCR products, samples from cells containing both,
SMN1 and SMN2, produced four bands (Figure 2B). The slowest
migrating band (top band) in a polyacrylamide gel represented the
Figure 1. Diagrammatic representation of SMN mRNA and SMN protein. Number of amino acids encoded by each exon is indicated. Exons
as well as domains they encode are shown as boxes. Domain functions are indicated.
doi:10.1371/journal.pone.0049595.g001
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exon 7 included transcripts from SMN1, whereas, three fast
migrating bands originated from SMN2.
Despite similar amount of starting material (RNA) used for RT-
PCR, we observed varied intensity of expected four bands in
different cell types. This could be due to a combination of factors,
including but not limited to variations in SMN1/SMN2 copy
numbers, transcription rate and splicing regulation. In order to
compare side-by-side the relative proportions of SMN1 versus
SMN2 transcripts in various cell types, loading of PCR products in
polyacrylamide gel was adjusted (Figure 2B). Our assay reliably
detected the presence and/or absence of major transcripts specific
to SMN1 and/or SMN2. For instance, the SMN1-associated top
band was absent in GM03813, a well-studied SMA type I patient
fibroblast cell line (Figure 2B, lane 14). Except GM03813, all other
cell lines in our screening showed the presence of SMN1.
Noticeably, GM20384, a BD patient lymphocyte cell line, lacked
all bands corresponding to SMN2, suggesting a complete or partial
deletion of both SMN2 alleles (Figure 2B, lane 3). None of the
other five BD patient lymphocytes showed the loss of SMN2
transcripts. To further ascertain that all exon 7-included products
in GM20384 originated from SMN1, we sequenced ten clones
derived from the top band (full-length transcript). All clones lacked
SMN2 associated signature mutations in exons 7 and 8, confirming
the absence of the intact SMN2 gene. Of note, donor of GM20384
had a mutation in CLN3 gene that is generally associated with BD
(Table 1) [61]. However, irrespective of the presence or absence of
SMN2, CLN3 mutations did not produce any change in splicing
pattern of SMN1 in any of the BD patient cell lines we tested
(Figure 2B). In addition, splicing pattern of SMN1 in GM20384
cells was similar to those in non-BD cell types. We believe that
GM20384 cells provide a valuable tool to understand SMN1-
specific splicing regulation.
A Unique Assay Captures Relative Expression of Major
Splice Isoforms of SMN1 and SMN2
To determine the relative abundance of major splice variants of
SMN1/SMN2 in a one-step reaction, we developed a PCR-based
assay that we named ‘‘MESDA’’. The 59 and 39 primers used in
MESDA annealed to SMN exons 2b and 8, respectively. Our
rationale to use 59 primer in exon 2b was based on the fact that
Figure 2. Splicing of endogenous SMN exon 7. A, Diagrammatic representation of exon/intron organization of SMN1 and SMN2 genes. Exonic
sequences are shown as colored boxes and intronic sequences are shown as lines/broken lines. Sizes of exons and introns are given. Size of the 39UTR
is based on the prevalently reported SMN1 transcript (NCBI accession number NM_000344). B, Splicing patterns of endogenous SMN1 and SMN2 exon
7 in different cell lines. Name of cell lines used are given on the top of the gel. Spliced products were analyzed by RT-PCR. We used 1 mg of total RNA
per 5 ml of reverse transcription reaction and generated cDNA employing random primers. SMN transcripts were amplified using primers P25 and P31.
To distinguish transcripts originated from SMN2, PCR products were digested with DdeI [55]. SMN1 and SMN2 transcripts are indicted on the right of
the gel. Exon 7-included (+) and exon 7-skipped (2) products are indicated on the left of the gel. Based on RT-PCR results, the presence and absence
of SMN1/SMN2 gene is marked by (+) and (2) respectively. The percentage of SMN2 exon 7 skipping was calculated based on the total value of SMN2
exon 7-included and exon 7-skipped products [55].The last 81 nucleotides of exon 1 are translated. Several mutations that distinguish SMN1 and
SMN2, including DdeI restriction site, as well as location of primers used for amplification of endogenous SMN transcripts are indicated.
doi:10.1371/journal.pone.0049595.g002
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this exon is constitutively spliced. Also, use of 59 primer in exon 2b
versus constitutively spliced exon 1 or exon 2a resulted in shorter
PCR products that can be better resolved on a polyacrylamide gel.
To maintain the sensitivity and an accurate estimate of the relative
molecular abundance of amplified products of different sizes, we
performed a limited-cycle radioactive PCR in which only one of
the primers was 59-radiolabeled. Considering that the 59 and 39
primers employed in MESDA annealed to exons 2B and 8 of
SMN, respectively, we were able to capture multiple splice
variants, including the transcripts generated by simultaneous
skipping of three exons of SMN. MESDA also identified novel
splice variants due to an entirely unexpected splice site pairings.
Cloning and sequencing confirmed identity of splice variants
generated by MESDA. GenBank accession numbers of novel
splice isoforms of SMN reported here are given in Table 2.
We employed MESDA to first profile major splice variants of
SMN1 and SMN2 in GM20384 and GM03813 cells, respectively.
SMN1 in GM20384 cells produced one predominant band
corresponding to the full-length transcript (Figure 3B, lane 2). In
addition, SMN1 showed very small but detectable skipping of exon
5 and exon 3. These results reveal for the first time the possibility
of alternative splicing of SMN1 exon 3 that codes for a critical
tudor domain. Previous studies have shown that tudor domain
plays an important role in nucleocytoplasmic trafficking of SMN
[25]. GM03813 cells showed two prominent bands corresponding
to the full-length and exon 7-skipped transcripts of SMN2. Similar
to SMN1 splice variants in GM20384 cells, we also detected
skipping of SMN2 exon 5 and exon 3 in GM03813 cells. However,
unlike SMN1, SMN2 showed co-skipping of exons 5 and 7 as well
as exons 3 and 7 (Figure 3B, lanes 1 and 2). We also observed
much weaker bands representing D3,5 and D3,5,7 transcripts in
GM03813 and GM20384 cells. As controls, we used GM20383
lymphocytes and undifferentiated neuronal SH-SY5Y cells. Since
these cells contain both, SMN1 and SMN2, they produced a
mixture of transcripts representing all SMN splice isoforms.
Interestingly, the results of MESDA revealed almost identical
splicing pattern of SMN in SH-SY5Y and GM20383 cells,
suggesting similarity in splicing of SMN between neuronal and
non-neuronal cells. However, compared to other cell types
examined, we observed higher expression of major SMN splice
variants in SH-SY5Y cells. Using cloning and sequencing, we next
characterized the relative abundance of SMN1 and SMN2
transcripts for specific splice variants in SH-SY5Y cells. Some
splice variants were also sequenced in other cell lines. In general,
we sequenced between 8 and 17 clones from major isoforms
Table 1. Cell lines used in this study.
No. Cell type Source Disease Description Cell Type
1 SH-SY5Y (CRL-2266) ATCC NB Unique marker on
Chromosome 1
Neuroblastoma
2 GM 20383 CCR BD/CL Juvenile CL, CLN3 mutations B-Lymphocyte
3 GM 20384 CCR BD/CL Juvenile CL, CLN3 mutations B-Lymphocyte
4 GM 20381 CCR BD/CL Juvenile CL, CLN3 mutations B-Lymphocyte
5 GM 20382 CCR BD/CL Juvenile CL, CLN3 mutations B-Lymphocyte
6 GM 08820 CCR BD/CL Juvenile CL, CLN3 mutations B-Lymphocyte
7 GM 08794 CCR BD/CL Juvenile CL, CLN3 mutations B-Lymphocyte
8 ND 00013 CCR PD Late onset DNA panel B-Lymphocyte
9 ND 00002 CCR PD Young onset DNA panel B-Lymphocyte
10 ND 00092 CCR Ctrl PD Convenience control B-Lymphocyte
11 AG 04159 CCR AD Familial, type 3 Fibroblast
12 GM 03814 CCR SMA Carr Mother (SMN1+/2) Fibroblast
13 GM 03815 CCR SMA Carr Father (SMN1+/2) Fibroblast
14 GM 03813 CCR SMA Child (SMN12/2), SMA Type I Fibroblast
Abbreviations: ATCC, American type cell collection; CCR, Coriell cell repositories; NB, Neuroblastoma; BD, Batten disease; CL, Ceroid lipofuscinosis; PD, Parkinson’s
disease; Ctrl, Control; AD, Alzheimer’s disease; SMA, Spinal muscular atrophy; Carr, Carrier.
doi:10.1371/journal.pone.0049595.t001
Table 2. Description and GenBank accession numbers of
splice variants reported in this study.
Exon Gene Cell line Treatment* GenBank accession number
D5 SMN1 GM20384 PQ-treated JQ657798
D3 SMN1 GM20384 PQ-treated JQ657800
D5,7 SMN1 GM20384 PQ-treated JQ657799
D5,6,7 SMN1 GM20384 PQ-treated JQ657801
D5,6 SMN1 GM20383 Untreated JQ732166
D5,6 SMN2 GM20383 Untreated JQ732167
D5 SMN1 SH-SY5Y PQ-treated JQ657802
D3 SMN2 SH-SY5Y PQ-treated JQ690861
D3,4 SMN1 SH-SY5Y PQ-treated JQ745297
D4,7 SMN2 SH-SY5Y PQ-treated JQ690864
D3,7 SMN2 SH-SY5Y PQ-treated JQ690862
D3,5 SMN1 SH-SY5Y PQ-treated JQ657803
D3,5,7 SMN2 SH-SY5Y PQ-treated JQ690863
D5,7 SMN2 SH-SY5Y Untreated JQ690865
D3,7 SMN1 SH-SY5Y Untreated JQ690867
D3,5 SMN2 SH-SY5Y Untreated JQ690866
D3,5,7 SMN1 SH-SY5Y Untreated JQ690868
*Represents whether splice isoforms were detected in untreated and/or PQ-
treated cells. PQ-treated refers to treatment of cells with 1 mM PQ for 24 h.
doi:10.1371/journal.pone.0049595.t002
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amplified by MESDA. DdeI digestion combined with sequence
analysis confirmed that isoforms lacking exon 7 came mostly from
SMN2 (Figure 4C and Figure S1). Based on sequence analysis,
transcripts containing exon 7 but lacking exon 5 or exon 3 were
generated mostly from SMN1 (Figure S1). It remains to be seen if
these results were affected by potentially different copy numbers of
SMN1 and SMN2 genes in SH-SY5Y cells. Our detection of SMN
transcript lacking exons 5 and 6 (D5,6) in GM20383 lymphocytes
was a novel and an unexpected finding. This transcript is
generated by an unusual pairing between the 59 ss exon 4 and
the 39 ss exon 7. Considering that the 39 ss SMN1 exon 7 is much
stronger than the 39 ss SMN2 exon 7, we expected a higher
occurrence of SMN1D5,6 compared to SMN2D5,6. Indeed,
sequence analysis revealed that an overwhelming majority of
D5,6 transcripts generated were from SMN1 (Figure S1A).
Effect of OS on Splicing of SMN Exons
Having established that various exons of SMN1/SMN2 are
alternatively spliced, we set out to distinguish between general
versus neuronal cell-specific effect of OS on SMN pre-mRNA
splicing. To induce OS, neuronal and non-neuronal cells were
treated with 1 mM PQ and transcripts were analyzed by MESDA
24 h post treatment. Of note, a previous study has shown that
1 mM of PQ is sufficient to produce a significant oxidative stress in
neuronal SH-SY5Y cells [60]. We observed OS-induced increase
in skipping of SMN2 exon 7 in all cell types treated with PQ
(Figure 4 and Figure S2). Based on results of DdeI digestion
(Figure 4C), the strongest effect of OS on splicing of SMN2 exon 7
was observed in GM20383 lymphocytes followed by neuronal SH-
SY5Y cells. Substantial skipping of SMN2 exon 7 was also
observed in GM03813 fibroblasts treated with PQ. Based on these
findings, we conclude that response to PQ-induced OS on splicing
of SMN2 exon 7 is universal. In addition, DdeI digestion analysis
underscores that OS-induced skipping of exon 7 is associated
mostly with SMN2 (Figure 4C). Supporting the reduced vulner-
ability of SMN1 exon 7 to skipping under OS, we detected very
low levels of SMN1 exon 7-skipped products in PQ-treated SH-
SY5Y cells (Figure 4C, lane 8).
We observed an increase in PQ-induced skipping of SMN1 exon
5 in GM20384 lymphocytes, suggesting that pre-mRNA splicing of
human SMN1 is sensitive to OS (Figure 4B). To validate that the
effect of OS on SMN1 exon 5 splicing is not specific to
lymphocytes and/or related to BD-causing mutations in CLN3
gene, we isolated and cloned RT-PCR products lacking exon 5
from PQ-treated SH-SY5Y cells. Based on sequence analysis,
conditions of OS led to an appreciable increase in SMN1D5
transcripts compared to SMN2D5 (Figure S1). These results
confirm that skipping of exon 5 is one of the major SMN1-
associated events in cells undergoing OS. Unlike SMN1, most
SMN2 transcripts that went through exon 5 skipping also lacked
exon 7. Consistently, we observed an enhanced co-skipping of
SMN2 exons 5 and 7 in PQ-treated GM03813 fibroblasts,
GM20383 lymphocytes and neuronal SH-SY5Y cells (Figure 4B).
Interestingly, PQ-induced OS caused a noticeable reduction in
intensity of several fast migrating exon 3-skipped splice variants
(D3, D3,5 and D3,7) in SH-SY5Y cells. Consistent with these
findings, results of quantitative real-time PCR (qPCR) using
various junction primers supported a decrease in skipping of exon
3 in PQ treated SH-SY5Y cells (Figure S3). However, due to a
near background level of expression of D3 transcripts, suppression
of exon 3 skipping under OS was not accompanied by an
appreciable increase in the exon 3-included transcripts.
Conditions of OS produced three additional novel SMN1 splice
variants that we captured in neuronal SH-SY5Y cells (Figures 4A
and 4B). The first such variant lacked SMN1 exons 4 and 7
(SMN1D4,7) and co-migrated with the SMND3 transcript in a
polyacrylamide gel (Figure 4B). Considering skipping of constitu-
tive exon 4 has not been previously reported and skipping of SMN1
exon 7 is an infrequent occurrence, presence of SMN1D4,7 was
very surprising. The second novel variant lacked SMN1 exons 3
and 4 (SMN1D3,4) and co-migrated with D3,5,7 transcripts on a
polyacrylamide gel (Figures 4A and 4B). The third novel SMN1
splice variant that we captured lacked exons 5, 6 and 7
(SMN1D5,6,7). Occurrence of SMN1D5,6,7 reveals for the first
time the feasibility of a rare phenomenon where three adjacent
exons of SMN are skipped.
All internal exons of SMN are divisible by three. Thus, skipping
of one or more internal exons of SMN does not create a premature
termination codon. Consequently, none of the alternatively spliced
variants of SMN are natural substrates of nonsense-mediated decay
(NMD). To analyze the translated products of various alternatively
spliced transcripts of SMN1 and SMN2, we performed western blot
analysis of PQ-treated GM20384 and GM03813 cells that carry
SMN1 and SMN2, respectively. In both cell types, we noticed a
decrease in SMN levels at 24 h post PQ treatment (Figure 4D).
However, we were unable to detect translated products corre-
sponding to any of the short transcripts generated from either
SMN1 or SMN2. This could be attributed to several factors,
including low levels of exon-skipped transcripts, slow rate of
translation under the conditions of OS and unstable nature of D7-
translated products. Of note, skipping of SMN exon 7 is known to
create a degradation signal [21].
Translation Efficiency of SMN Transcripts Lacking Internal
Exons
In order to determine whether proteins encoded by transcripts
that lack one or more internal SMN exons could be produced, we
employed an alternative approach. We induced SMN2 exon
skipping in HeLa cells using two ASOs: E3/I3Jxn and E5/I5Jxn
(Figure 5A). E3/I3Jxn and E5/I5Jxn blocked the 59 ss of exon 3
and exon 5, causing massive skipping of exon 3 and exon 5,
respectively (Figure 5B). Targeting ASOs did not discriminate
between SMN1 and SMN2 transcripts that code for identical
proteins. Also, ASOs were designed not to interfere with the
translational machinery because they annealed to sequences that
are removed during pre-mRNA splicing. Our approach provided
high levels of SMN exon-skipped transcripts that served as the
needed templates for protein synthesis. As a result, we were able to
detect proteins generated from transcripts lacking either exon 3 or
5 (Figure 5C, lanes 2 and 3). SMND5 appeared to be stable and
migrated very close to the full-length SMN. On the other hand,
SMND3 seems to be less stable. Poor stability of SMND3 could be
attributed to its misfolding due to the loss of the tudor-domain
coded by exon 3. Our results validate that SMND3 and SMND5
transcripts could be translated. Whether SMND3 and SMND5
proteins play any physiological role is a matter of future
investigation.
Effect of Promoter on OS-induced Skipping of SMN
Exon 7
Promoter structure (sequence) has been shown to affect
alternative splicing of specific exons in several genes including
fibronectin (FN), calcitonin-gene-related product (CGRP) and
CD44 [62,63,64]. SMN promoter has been localized in a 2 kb
region upstream of the coding sequence that starts within exon 1
[65]. Using reporter assays, two earlier studies support similarity of
promoter activity between SMN1 and SMN2 [65,66]. Based on
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effect of small compounds that act as inhibitors of histone
deacetylase 1, recent reports suggest the role of promoter
sequences in splicing regulation of SMN exon 7 [50,67]. However,
there is no study to implicate a direct role of SMN promoter
sequence on usage of exon 7. To address the promoter-specific
splicing regulation of SMN2 exon 7 under normal and OS
conditions, we employed SMN minigenes with three different
promoters: cytomegalovirus (CMV), thymidine kinase (TK) and
wild type SMN1/SMN2 promoters (Figure 6A). Several CMV
promoter-containing minigenes encompassing SMN genomic
sequences from exon 6 through exon 8 cloned in pCI vector
(Promega) have been reported [19,68,69]. We took advantage of
CMV promoter containing short minigenes that maintained an
earlier reported deletion within intron 6 [68]. Due to decreased
size, these minigenes provide desired benefit of high transfection
efficiency without any apparent change in splicing pattern of SMN
exon 7. To generate minigenes under the control of wild type
SMN1 and SMN2 promoters, we replaced CMV promoter with
Figure 3. Detection of multiple exon skipping events in endogenous SMN. A, Diagrammatic representation of the SMN gene. Exonic and
intronic sequences are depicted as in (Figure 2A). Dotted lines indicate skipping of previously reported exons and/or novel splice variants. Annealing
positions of primers used for MESDA are shown. B, Multiple splice isoforms of endogenous SMN pre-mRNA in different cell lines. Name of cell lines
used are given on the top of the gel. Splice products were analyzed by RT-PCR. We used 1.4 mg of total RNA per 10 ml of reverse transcription reaction
and generated cDNA employing oligo(dT)12–18 primer. SMN transcripts were amplified using primers 59hSMN-E2b (anneals within Exon 2b) and P2–2
(anneals within Exon 8). Diagrammatic representation of splice variants is given on the left of the gel; their sizes are indicated on the right of the gel
with names of skipped exons given in brackets. For intra-lane comparison of bands, pictograms (shown on right) were generated for each lane by
MultiGauge software version 3.0 (FUJIFILM). The identity of splice variants was established by sequencing. Novel splice variant is marked by a star.
Note that 567-nucleotide-long D5,6 variant moves slower than 573-nucleotide-long D3 variant. FL, full length; NS, non-specific. The number of SMN1
and SMN2 transcripts for each of splice variants, except for the full-length and D7, was determined by sequencing of at least 8 randomly selected
clones per variant (Figure S1).
doi:10.1371/journal.pone.0049595.g003
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,3.5 kb genomic sequences harboring promoter region of SMN1
and SMN2, respectively. Wild type SMN1 and SMN2 promoters
used in this study were the same as reported in an earlier study that
confirmed similarity of transcriptional regulation between two
SMN genes [66]. To generate TK promoter-containing minigenes,
we subcloned SMN genomic sequences from pCI-based SMN
minigenes into commercially available pTK-GLuc vector (New
England Biolabs). Other than variations in promoter structures,
vector-specific sequences downstream of promoters brought
additional differences in the contexts of the three minigenes we
used (Figure 6A and Figure S4). Therefore, the design of our
minigene constructs allowed us to simultaneously examine the
effect of promoters as well as sequences upstream of the SMN
splicing cassette. We employed neuronal SH-SY5Y cells to
examine the splicing pattern of SMN minigenes expressed under
the control of different promoters. We simultaneously monitored
the splicing pattern of exon 7 derived from endogenous SMN1 and
SMN2.
Among three promoters used in this study, we observed
substantially higher levels of SMN expression with CMV promoter.
For the purposes of comparison of splice variants, we adjusted
loading of PCR products for different promoter samples. All
minigenes expressing SMN under the control of various promoters
recapitulated the splicing pattern of endogenous gene, with
predominant exon 7 skipping in SMN2, and predominant exon
7 inclusion in SMN1 (Figure 6B). However, unlike minigenes
under the control of TK and CMV promoters, wild type promoter
produced noticeably less exon 7 skipping (Figure 6B, lane 4).
These results provide the first direct evidence of the role of
promoter structure in modulation of SMN exon 7 splicing.
However, compared to a reported 10-fold decrease in usage of
the extra domain I (EDI) exon of FN when expressed under
control of a CMV promoter [64], impact of SMN promoter on
percentage of exon 7 skipping could be considered as less
prominent (Figure 6B, compare lanes 1 and 2 with lanes 9 and
10). Effect of promoter structure on SMN exon 7 splicing was
further supported by an appreciable change in the levels of exon 7
inclusion when CMV promoter was exchanged with TK promoter
in SMN minigenes (Figure 6B, compare lanes 5 and 6 with lanes 9
and 10). Interestingly, SMN2 transcripts derived from endogenous
gene showed ,13% less exon 7 skipping as compared to SMN2
minigene expressed under wild type promoter (compare Figure 6B
with Figure 6C). This difference could be attributed to the context
of the endogenous gene, which is subjected to chromatin
remodeling during transcription elongation. Considering rate of
transcription elongation and transcriptional pausing affects the
outcome of alternative splicing [5,70,71], a moderate difference in
splicing of SMN2 exon 7 between full endogenous gene and
minigene is expected.
Treatment of SH-SY5Y cells with PQ caused noticeable
increase in skipping of SMN exon 7 from all minigenes expressed
under different promoters. However, distinctions between SMN1
and SMN2 exon 7 splicing under the conditions of OS were more
pronounced in the context of endogenous promoter followed by
the expression under wild type promoter. For instance, under the
conditions of OS, levels of exon 7-containing SMN2 transcripts
decreased ,2-fold and more than 2.5-fold and in the context of
wild type and endogenous promoters, respectively (Figure 6B,
lanes 1 and 2; Figure 6C). At the same time, levels of exon 7-
containing SMN1 transcripts in these contexts decreased only
marginally. SMN1 expressed under the control of TK promoter
produced appreciable exon 7 skipping. Also, SMN1 expressed
under the control of TK promoter caused the highest levels exon 7
skipping under the conditions of OS (Figure 6B, lanes 7 and 8).
Overall, our results support the role of promoter sequence in
regulation of SMN exon 7 splicing under the conditions of OS.
However, promoter sequences were not the sole regulatory
elements to affect OS-induced SMN exon 7 splicing. Considering
SMN1 expressed under all promoters maintained the high levels
(.60%) of exon 7-included transcripts even under the conditions
of OS, cis-elements within SMN exon 7 and/or within flanking
intronic sequences also contribute towards OS-induced exon 7
skipping (Figure 6B, lanes 4, 8 and 12).
A Short ASO Targeting an Intronic GC-rich Silencer Fully
Prevents OS-induced Skipping of SMN2 Exon 7
One of the fundamental questions in stress-related studies is to
establish whether exon-specific aberrant splicing under OS is
preventable. Considering the well-characterized nature of various
negative cis-elements, SMN2 exon 7 splicing offers an ideal system
to test this hypothesis. We have earlier reported that a 15-
nucleotide-long intronic splicing silencer N1 (ISS-N1) and an
overlapping 8-nucleotide-long GC-rich sequence play critical role
in SMN2 exon 7 skipping (Figure 7A) [48,53,72,73]. An 8-mer
ASO (3UP8) targeting GC-rich sequence prevents SMN2 exon 7
skipping with high target specificity without any off-target effect on
splicing of other SMN exons [53]. Therefore, we used 3UP8 to
examine whether it will alleviate the negative effect of PQ-induced
OS on splicing of SMN2 exon 7. We first treated GM03813 cells
with 50 nM of 3UP8 for 24 h and then induced OS by exposing
the cells to 1 mM PQ. Cells were harvested 24 h post PQ
treatment and transcripts were isolated for analysis by MESDA. As
shown in Figure 7B, 3UP8 was able to fully prevent SMN2 exon 7
skipping even under PQ-induced OS. As expected, the effect of
3UP8 was exon 7 specific since this ASO did not change the
splicing pattern of other SMN2 exons. We also used a control ASO
with a single mismatch mutation. The control ASO had no effect
Figure 4. Effect of PQ treatment on splicing of SMN. A, Diagrammatic representation of the SMN gene. Exonic and intronic sequences are
depicted as in (Figure 2A). Dotted lines indicate exon skipping that generated novel splice variants. Annealing positions of primers used for MESDA
are shown. B, Detection of multiple exon skipping events in endogenous SMN in the presence (+) and absence (2) of PQ. Names of cell lines used are
given on the top of the gel. Total RNA was prepared from cells treated with 1 mM of PQ for 24 hours. Splice products were analyzed by RT-PCR as
described in Figure 3B. Diagrammatic representation of splice variants is given on the left of the gel; their sizes are indicated on the right of the gel
with names of skipped exons given in brackets. The identity of splice variants was confirmed by sequencing. Note that 513-nucleotide-long D5,6,7
variant moves slower than 519-nucleotide-long D3,7 variant. Novel splice variants are marked by stars. FL, full length; NS, non-specific. For intra-lane
comparison of bands, pictograms were generated for each lane (Figure S2). C, Splicing patterns of endogenous SMN exon 7 in the presence (+) or
absence (2) of PQ. Names of cell lines used are given on the top of the gel. Total RNA was prepared from cells treated with 1 mM of PQ for 24 hours.
Spliced products were analyzed by RT-PCR as described in panel B except primers P25 and P31 were used for PCR amplification step. To distinguish
transcripts originated from SMN2, PCR products were digested with DdeI [55]. SMN1 and SMN2 transcripts are indicted on the right of the gel. Exon 7-
included (+) and exon 7-skipped (2) products are indicated on the left of the gel. The percentage of SMN2 exon 7 skipping was calculated as in
Figure 2B. D, Western blot showing translated products generated from SMN in GM20384 and GM03813 cells treated with PQ for 24 h. We loaded 50
and 80 mg of protein from GM20384 and GM03813 cell lysates, respectively. Primary antibodies used for probing are indicated on the left of the gel.
Although the predicted molecular mass of SMN is 32 kDa, it migrates as 40 kDa band due to posttranslational modifications.
doi:10.1371/journal.pone.0049595.g004
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on splicing of SMN2 (Figure 7B). To validate that the effect of
3UP8 is not due to a general stimulation of splicing machinery, we
examined the splicing pattern of Procollagen-lysine 2-oxoglutarate 5-
dioxygenase 2 (PLOD2) exon 14 that we determined to be also
affected by PQ-induced OS. 3UP8 had no stimulatory effect on
splicing of PLOD2 exon 14 (Figure S5).
Since OS affects SMN2 exon 7 splicing the most, leading to a
decrease in the production of the full-length transcripts, we next
examined whether treatment with PQ has an effect on levels of
SMN protein in SMA patient cells. For this, we performed western
blot analysis using lysates from cells treated similarly as described
in Figure 7B. Consistent with the decrease in full-length transcript,
OS produced a reduction in levels of SMN (Figure 7C). However,
we did not detect SMND7, a truncated protein likely to be
produced by translation of SMN2 exon 7-skipped transcript, the
most predominant splice variant generated under OS. This could
be due to high instability of SMND7 shown to contain a protein
degradation signal [21]. Similar signal would affect stability of
SMND5,7 that could be generated by translation of the second
most predominant transcript lacking exons 5 and 7. Gemin2 is a
Figure 5. Translational efficiency of transcripts generated by ASO-induced skipping of SMN exons in HeLa cells. A, Diagrammatic
representation of SMN pre-mRNA showing annealing positions of ASOs. Exonic and intronic sequences are depicted as in (Figure 2A). B, Splicing
pattern of endogenous SMN in HeLa cells treated with various ASOs. Names of ASO used are given on the top of the gel. HeLa cells were transfected
with 100 nM of an individual ASO. Cells were collected for total RNA preparation,38 hours post transfection. Spliced products were analyzed by RT-
PCR as described in Figure 3B. Diagrammatic representation of spliced variants is given on the left of the gel; their sizes are indicated on the right of
the gel with names of skipped exons given in brackets. All spliced products represent mixture of transcripts generated from both, SMN1 and SMN2. C,
Western blot showing SMN protein isoforms generated from transcripts in panel B. Cells were collected for whole-cell lysate preparation ,38 hours
post transfection. In order to capture the low abundance of SMND3 isoform, we loaded 50 mg of protein from sample treated with E3/I3 Jxn ASO.
Protein loading was confirmed by re-probing the blot with anti-b-actin antibodies. Primary antibodies used for probing are indicated on the left of
the gel; whereas, SMN isoforms are shown on the right of the gel. SMN is present in all lanes. SMND3 is detectable in lane 2, whereas SMND5 is
detectable in lane 3.
doi:10.1371/journal.pone.0049595.g005
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critical SMN-interacting partner responsible for the formation of
SMN complex that participates in snRNP biogenesis [24–26]. PQ-
induced decrease in SMN levels was accompanied by a similar
reduction in Gemin2, suggesting a potential adverse effect of PQ
on snRNP biogenesis. Remarkably, ASO treatment that restored
SMN2 exon 7 inclusion also produced increased levels of SMN and
Figure 6. Effect of PQ on splicing of different SMN minigenes. A, Diagrammatic representation of promoter and exon/intron organization in
different minigenes as compared to endogenous SMN. Promoters and exons are shown as boxes, introns are indicated as lines. Alternatively spliced
exons 3, 5 and 7 are shown as colored boxes. Dotted lines indicate deleted sequences. Wild type refers to the minigenes under the control of human
SMN1/2 promoters; TK, minigenes under the control of thymidine kinase promoter; CMV, minigenes under the control of CMV promoter. In CMV and
TK minigenes, solid bar before exon 6 refers to a vector-specific sequences (Figure S4). Locations of primer pairs for the amplification of spliced
products have been marked by arrows. B, In vivo splicing pattern of different SMN1 and SMN2 minigenes. Data were generated using total RNA from
SH-SY5Y cells transfected with 1 mg of an indicated minigene and treated with PQ for 21 h. Minigene splice products were analyzed by RT-PCR. We
used 0.5 mg of total RNA for 5 ml of reverse transcription reaction and generated cDNA employing oligo(dT)12–18 primer. Loading was adjusted so that
the intensity of bands between samples was comparable. Exon 7-included and skipped products are indicated on the left of the gel. Due to the
change in location of the primer annealing sites, SMN spliced products generated from different vectors have variable lengths. The results were
analyzed as previously described [55]. Abbreviations are same as described in panel A. C, Effect of PQ on splicing of endogenous SMN exon 7. Splice
products were analyzed by RT-PCR as described in panel B, except we used N-24 and P26 primers for PCR to specifically amplify endogenous SMN. Of
note, P26 anneals to exon 8 region, which is absent in minigenes [55]. To distinguish spliced variants originated from SMN2, PCR products were
digested with DdeI [55]. The percentage of SMN2 exon 7 skipping was calculated as described in Figure 2B. Labeling was the same as described in
panel A and Figure 2B.
doi:10.1371/journal.pone.0049595.g006
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Gemin2 (Figure 7C). Considering several ASO-based strategies to
correct SMN2 splicing in SMA have been proposed [42–47], our
findings are significant as they suggest that these strategies will
retain their efficacy even under OS conditions.
Discussion
Occurrence of aberrant splicing under the conditions of OS is
an area of growing interest due to its correlation with major
human diseases including cancer, cardiovascular and neurode-
generative disorders. The fundamental issue of specificity with
which OS affects splicing of certain exons of particular genes in
specific tissues remains poorly understood. Here, we use human
spinal muscular atrophy genes (SMN1 and SMN2) as a represen-
tative system to understand the impact of OS on alternative
splicing of various exons of two nearly identical genes. The full-
length transcripts from both genes code for SMN, an essential
protein that plays a central role in gene regulation through snRNP
biogenesis [24]. Skipping of any of the seven internal exons of
SMN results in the loss of a fully functional protein that contains
several overlapping domains with defined roles. Our study
addresses an important question of prioritization of splicing events
by which each copy of a duplicate gene responds differently to the
conditions of OS.
Publically available SMA patient fibroblast cell line (GM03813)
that lacks SMN1 has been widely used for drug screening as well as
for understanding transcriptional and posttranscriptional regula-
tion of SMN2. However, analogous cell line to examine SMN1-
specific transcriptional and posttranscriptional regulation has not
been found. Consequently, a side-by-side comparison of the major
splice variants of SMN1 and SMN2 has not been reported. We
serendipitously discovered a BD patient cell line (GM20384) that
lacked major transcripts specific to SMN2. Such occurrence could
be due to complete or partial deletion of SMN2 genes. The splicing
pattern of SMN1 exon 7 in GM20384 cells appeared to be
identical to those observed in other cell types including BD,
Parkinson’s disease, Alzheimer’s disease and neuronal SH-SY5Y
cell lines, all of which carried SMN2. Here, we took advantage of
GM20384 cell line as a model system to examine SMN1-specific
splicing regulation.
In order to reliably capture the relative abundance of major
transcripts of SMN, we resorted to develop MESDA. The defining
feature of MESDA was the simultaneous evaluation of splicing of
five internal exons (exons 3, 4, 5, 6 and 7), among which exons 3, 5
and 7 are known to be alternatively spliced. On the expected lines,
GM03813 cells produced two abundantly expressed splice variants
corresponding to the full-length and SMN2 exon 7-skipped
(SMN2D7) transcripts (Figure 3B, lane 1). In addition, GM03813
cells generated SMN2D5,7 and SMN2D5 as the third and fourth
most abundant transcripts, respectively. Low levels of SMN2D5 as
compared to SMN2D5,7 was somewhat surprising as it suggested a
cooperative mode of action in which spliced intermediates lacking
SMN2 exon 7 served as a preferred substrate for exon 5 skipping.
GM03813 cells produced very low levels of SMN2D3, SMN2D3,7,
SMN2D3,5 and SMN2D3,5,7 transcripts, demonstrating the
feasibility of all combinations of co-skipping events of three
alternate exons of SMN2. Among low abundant novel isoforms, we
identified D5,6 transcript in GM20383 lymphocytes (Figure 3B,
lane 3). The infrequent occurrence of this splice variant could be
ascribed to a rare paring of the 59 ss of exon 4 with the 39 ss of
exon 7, which itself is an alternatively spliced exon. Considering
C6U mutation in SMN2 creates a weak 39 ss of exon 7, we
observed substantially less SMN2D5,6 transcripts compared to
SMN1D5,6 transcripts in GM20383 lymphocytes.
Beyond a handful studies reported more than a decade ago on
exon 7- and exon 5-skipped transcripts [18,19,58], our under-
standing of transcript diversity generated by endogenous SMN1
remains very limited. Therefore, several of our findings reported
here on SMN1 splicing constitute a significant advancement
towards a better understanding of an overall posttranscriptional
regulation of SMN1, which serves as the primary source for
maintaining healthy SMN levels in general population. Our results
established that the skipping of SMN1 exons 3 and 5 is a general
phenomenon that occurs in neuronal and non-neuronal cells alike.
Based on the conserved nature of a sequence spanning from exon
2a through exon 6 of SMN genes, one could speculate that the
mechanism of splicing of exons 3 and 5 is the same for SMN1 and
SMN2. However, lack of SMN1D5,7 transcripts owing to the
absence of SMN1 exon 7 skipping was not accompanied by a
proportionate gain in SMN1D5 transcripts, suggesting that
inclusion of SMN1 exon 7 has a favorable effect on inclusion of
exon 5. This could be due to the supporting role of a new sequence
and/or structural context created by the inclusion of exon 7.
Interestingly, we observed about 13-fold more SMN1 exon 3
skipping as compared to SMN2 exon 3 skipping in neuronal SH-
SY5Y cells. Also, as compared to SMN2D3 transcripts, less
proportion of SMN1D3 transcripts underwent through co-skipping
with exon 5 (Figure S1). These results suggest an inverse
correlation between skipping events of exon 3 and exon 5 of
SMN1. Our subsequent finding that PQ-induced enhanced
skipping of SMN1 exon 5 suppresses generation of D3 transcripts
supports such mechanism (Figure 4B). It remains to be seen if such
correlation is due to the predominant inclusion of exon 7 in SMN1.
Effect of PQ-induced OS on splicing in different cell types
(GM03813, GM20384, GM20383 and SH-SY5Y) revealed
remarkable similarities as well as differences between two SMN
genes. Supporting an earlier report [60], PQ-induced OS
produced a significant skipping of SMN2 exon 7, whereas SMN1
exon 7 splicing remained mostly unaffected (Figure 4C). However,
the sensitivity of our assay combined with the cell types used
demonstrated that high susceptibility of SMN2 exon 7 to skipping
Figure 7. Treatment of SMA patient fibroblasts with 3UP8 ASO abrogates the negative effect of PQ. A, Diagrammatic representation of
the ASO target area in SMN intron 7. Negative regulators of exon 7 splicing, GC-rich sequence, ISS-N1 and hnRNPA1 binding sites are highlighted with
boxes. Annealing positions and sequences of ASOs (3UP8 and CONT) are given in 39 to 59 direction. 3UP8 and CONT (3UP8/64A) ASOs are the same as
reported [53]. Numbering of nucleotides starts from the first position of intron 7. B, Splicing pattern of endogenous SMN2 in SMA patient fibroblasts
transfected with different ASOs in the presence (+) or absence (-) of PQ. GM03813 fibroblasts grown in 100 mm dishes were transfected with 50 nM
of an ASO. About 24 hours after transfection, PQ was added to cells with a fresh growth medium at a final concentration of 1 mM. Cells were
collected for total RNA/protein preparation 24 h post treatment. Spliced products were analyzed by RT-PCR. We used 1.2 mg of total RNA per 10 ml of
reverse transcription reaction and generated cDNA employing 39E8-Dde primer. Splice isoforms are indicated on the left of the gel as shown in panel
(i). Mock refers to untransfected cells. Relative abundance of SMN spliced isoforms was calculated in each sample and is shown as a bar diagram given
in panel (ii). Error bars based on standard error of the mean have been described in panel (iii). *, P,0.05; **, P,0.01; NS, not statistically significant. C,
Western blot showing the levels of SMN and its interacting partner, Gemine2, in SMA patient fibroblasts transfected with 3UP8 or control (CONT) ASO
in the presence (+) and absence (2) of PQ. We used 20 mg of total protein for each sample. Equal protein loading was confirmed by re-probing the
blot with anti-b-actin antibodies. Primary antibodies used for probing are indicated on the left of the gel.
doi:10.1371/journal.pone.0049595.g007
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under the conditions of OS is more general than previously
thought. Consistently, all SMN2-containing cells in our study
showed substantial SMN2 exon 7 skipping under conditions of OS.
We show that OS-induced skipping of SMN2 exon 5 happens
primarily (if not exclusively) as co-skipping of SMN2 exons 5 and 7
(Figure 4B, lane 2). By contrast, skipping of SMN1 exons 5 under
conditions of OS takes place almost always without skipping of
SMN1 exon 7 (Figure 4B, lane 4). Our results also demonstrate
that OS-induced skipping of SMN exon 5 occurs in both, neuronal
and non-neuronal cells. Exon 5 of SMN codes for a recently
described proline-rich calpain cleavage domain [27]. Owing to the
low levels of SMN1D5 transcripts, we could not detect SMND5
protein under the conditions of OS (Figure 4D). However, our
finding that SMND5 is stably translated is significant (Figure 5C).
Future studies will address if the calpain cleavage domain lacking
protein (SMND5) generated by SMN1D5 has any physiological
significance.
Skipping of any of the internal exons of SMN maintains the
reading frame. Therefore, NMD pathway that degrades mRNAs
carrying a premature termination codon is not applicable for the
reduced levels of any of the short SMN transcripts. We detected
three novel SMN1 isoforms (SMN1D4,7; SMN1D3,4 and
SMN1D5,6,7) generated under the conditions of OS. It is not
known if low abundance of these splice variants are in part due to
their poor stability caused by a non-NMD mechanism. Presence of
SMN1D4,7 underscores the occurrence of a rare splicing event of
exon 4 skipping in which the 59 ss of exon 3 and the 39 ss of exon 5
are required to pair. Considering exons 3 and 5 are also
alternatively spliced, skipping of exon 4 represents a unique event
that guarantees promotion of inclusion of both, exons 3 and 5.
Therefore, our finding of SMN1D4,7 reveals the first mutually
exclusive event with a significance to the prevention of skipping of
two alternatively spliced exons of SMN1. Also, generation of
SMN1D4,7 comes at the expense of competing events that lead to
production of two novel isoforms: SMN1D3,4 and SMN1D5,6,7.
Presence of SMN1D5,6,7 underscores a unique splicing event
requiring a rare long-distance pairing between the 59 ss of exon 4
and the 39 ss of exon 8. Another significant observation of our
study was the stimulatory effect of OS on splicing of exon 3
(Figures S2 and S3). It remains to be seen if decrease in exon 3
skipping under the conditions of OS contributes at least in part
towards generation of some of the novel splice variants describe
above.
Increasing evidence support transcription-coupled splicing
regulation. Effect of transcription on alternative splicing could be
exerted through transcription initiation at specific promoters as
well as through transcriptional pausing [5]. Well-known factors
that affect alternative splicing in a promoter-specific manner
include steroid hormone nuclear receptor coactivators, human
papilloma virus (HPV) transcriptional activator E2 and peroxi-
some proliferator-activated receptor coactivator-1a (PGC-1a)
[64]. Our finding that large wild type promoter sequence in our
reporter system suppresses skipping of SMN exon 7 provided the
first direct evidence of the role of promoter in regulation of SMN
exon 7 splicing. Effect of promoter sequence on regulation of SMN
exon 7 splicing was also observed under the conditions of OS. In
particular, OS-induced differential splicing regulation between
SMN1 and SMN2 was much more apparent in the context of the
wild type promoter as compared to CMV and TK promoters.
Decreased ATP level in OS is likely to slow down or even pause
transcription elongation with a significant consequence to ss
selection and exon usage [70,71]. Generation of a long endoge-
nous transcript requires an extensive transcription elongation step.
Therefore, it is likely that the effect of OS is exerted mostly at the
level of transcription elongation. Our finding that endogenous
SMN2 produced the highest degree of exon 7 skipping under the
conditions of OS also supports the role of transcription elongation
in OS-induced splicing regulation of SMN2 exon 7. Recently,
transcriptional elongation regulator 1 (TCERG1) has been found
to regulate alternative splicing of the short isoform of B-cell
lymphoma-extra (BCL-xs) [74]. It remains to be seen if analogous
mechanism accounts for the regulation of SMN2 exon 7 splicing
under the conditions of OS. However, our results do not preclude
the role of additional factors that act through transcription
initiation albeit variably at different promoters expressing SMN
minigene under the conditions of OS.
Translation of specific transcripts is selectively affected under
the conditions of stress [75]. Our finding that ASO-mediated
prevention of SMN2 exon 7 skipping under the conditions of OS is
able to restore the levels of SMN and Gemin2 suggests that OS
does not affect selective repression of SMN translation. Given the
prominent role of SMN in cellular metabolism, it is imperative
that cells maintain a minimum SMN level even under the
conditions of OS. Selective skipping of exon 7 from one gene
(SMN2) but not from the other (SMN1) supports this argument.
Although D7 and D5,7 were the most abundant SMN2 transcripts
generated under OS, we could not detect their corresponding
translated products. This could be due to a protein degradation
signal coded by the exon 7-skipped transcripts [21]. Our ASO-
based approach ruled out an analogous degradation mechanisms
for the translated product generated from D3 and D5 splice
variants. Cells prioritize mRNA translation and storage under
stress-associated conditions [75]. Hence, it is possible that shorter
splice variants of SMN served as decoy molecules to capture
microRNAs (miRNAs) and relieve full-length transcripts of
miRNA repression. This mechanism will allow a better synthesis
of SMN even from the low levels of full-length transcripts. A recent
report provides a strong proof of principle for such mechanism in
an analogous system [76]. miRNA-associated translational repres-
sion is generally associated with the 39 untranslated regions
(UTRs) [77]. However, it (repression) could also occur through
targets within isoform-specific coding sequences [77,78]. Given the
fact that PQ treatment generates an altered 39 UTRs due to
overwhelming skipping of the last coding exon (exon 7) and also
produces additional splice variants, there is a plausible possibility
of miRNA-associated control of SMN levels in stress-associated
conditions. Now that we have confirmed the vulnerability of
various SMN exons to skipping under the conditions of OS, future
experiments would address the mechanism of OS-induced
aberrant splicing regulation of SMN and the physiological role of
various SMN transcripts generated under stress-associated condi-
tions.
In summary, our findings uncover the surprising diversity of
SMN transcripts expressed under normal and OS conditions. We
validate our findings employing several complementary approach-
es including MESDA and a unique cell type devoid of major
SMN2 transcripts. Our findings underscore an added vulnerability
of SMA patients to the conditions of OS and demonstrate the
efficacy of an ASO-based strategy in splicing correction under OS.
Our results provide the first direct evidence of role of SMN
promoter sequence in regulation of SMN exon 7 splicing under
normal and OS conditions. In addition to a better understanding
of SMA pathogenesis, our findings bring new perspective to
splicing regulation of a model housekeeping gene associated with
one of the leading genetic causes of infant mortality.
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Materials and Methods
Plasmid Constructs
Minigene splicing cassettes pSMN1DI6 and pSMN2DI6 have
been described previously [68]. Designs of newly constructed
minigenes and primer sequences for cloning are given in
supporting data (Table S1, Figure S4). Briefly, pTK-SMN1DI6
and pTK-SMN2DI6 constructs, in which SMN minigene sequenc-
es were placed under the control of Herpes Simplex Virus (HSV)
thymidine kinase (TK) promoter, were generated as follows. SMN1
and SMN2 sequences were amplified by polymerase chain reaction
(PCR) using pSMN1DI6 and pSMN2DI6 as templates, respec-
tively. The amplification was performed with Phusion DNA
Polymerase (New England Biolabs) and a pair of primers, P42 and
P43. PCR products were then digested with HindIII and BamHI
and inserted into pTK-GLuc vector (New England Biolabs)
treated with the same restriction enzymes. To generate splicing
cassettes pWTP-SMN1 and pWTP-SMN2 in which SMN1 and
SMN2 minigene sequences were placed under the control of
human SMN1 and SMN2 promoters, respectively, we started with
PCR amplification of the SMN1 and SMN2 promoter sequences
(,3.5 kb) using T1 and C1 clones, respectively [66]. The
promoter sequences were amplified using Phusion DNA Polymer-
ase and primers 59SMN-pro-BglII and 39SMN-pro-XhoI. The
amplified SMN1 and SMN2 promoter sequences were subsequent-
ly digested with BglII and XhoI and ligated into pSMN1DI6 and
pSMN2DI6 minigenes subjected to partial digestion with the same
restriction enzymes. Partial digestion was used since pSMN1DI6
and pSMN2DI6 minigenes contain two BglII restriction site. For
partial digestion several mg of pSMN1DI6/pSMN2DI6 were
treated with XhoI (6.4 U) at 37uC overnight; next morning BglII
(4 U) was added to the reaction mixture and digestion continued
for another 15 min followed by phenol:chloroform extraction and
ethanol precipitation. The precipitated products were separated
on a 1% agarose gel, the band of interest corresponding to 4.2 kb
was excised from the gel and the DNA product was recovered
from the gel using QIAquick Gel Extraction Kit (Qiagen) as per
manufacturer’s instructions. The recovered DNA corresponded to
either BglII- and XhoI-digested pSMN1DI6 or pSMN2DI6,
which, as mentioned above, were used in ligation reaction with
SMN1 and SMN2 promoters and Quick Ligation Kit (New
England Biolabs). The identity of novel minigene clones was
verified by sequencing. All primers were obtained from Integrated
DNA Technologies (Table S1). All restriction enzymes used were
from New England Biolabs.
Cell Culture and ASOs
All tissue culture media and supplies were purchased from
Life Technologies. Human neuroblastoma SH-SY5Y cells were
cultured in 1:1 mixture of Minimum Essential Medium (MEM,
catalog # 11095) and F12 medium supplemented with 10%
fetal bovine serum (FBS). Primary patient fibroblasts, immor-
talized B-lymphocytes as well as cells from healthy individuals
were obtained from Coriell Cell Repositories (CCR). Descrip-
tion of cells from CCR used in this study is given in Table 1.
These cells were grown according to the provided instructions.
In brief, all primary fibroblasts were grown in minimal essential
medium (MEM, catalog # 10370) supplemented with 2 mM
GlutaMAX-I and 15% FBS. Only in case of primary fibroblasts
from Alzheimer patient (Repository number AG04159), the
amount of FBS in growth medium was 10%. B-lymphocytes
were grown in RPMI1640 (catalog # 11875) medium
supplemented with 15% FBS. The following ASOs were used
in this study: 3UP8, 59-mG*mC*mU*mG*mG*mC*mA*mG-39;
3UP8/64A (CONT), 59-mG*mC*mU*mG*mU*mC*mA*mG-
39; E3/I3Jxn, 59-mU*mA*mU*mC*mC*mU*mU*-
mA*mC*mC*mU*mC*mU*mU*mG*mA*mG*mC*mA*mU-39;
E5/I5Jxn, 59-U*mU*mU*mA*mC*mU*mU*mA*mC*-
mU*mG*mG*mU*mG*mG*mU*mC*mC*mA*mG-39. All
ASOs were obtained from Dharmacon Inc. They incorporated
29-O-methyl modification (indicated by ‘‘m’’) and phosphor-
othioate backbone (indicated by *) as described earlier [48].
PQ Treatment
PQ (Paraquat, methyl viologen dichloride hydrate, catalog #
856177) was obtained from Sigma. PQ treatment of pre-plated
adherent cells was done as follows. Sixteen to eighteen hours
before the treatment GM03813 cells were plated at a density of
,1.16105 cells per well of 6-well plates or ,6.26105 per 100 mm
tissue culture dish. For SH-SY5Y, ,1.96106 and 0.56106 SH-
SY5Y cells were seeded in 100 mm dishes. In case of SH-SY5Y,
cells plated at a higher density were subjected to PQ treatment,
while cells seeded at a lower density served as an untreated control.
Lower cell density insured that untreated control SH-SY5Y cells
do not become confluent at the end of PQ treatment. PQ was
added with fresh growth medium at a final concentration of
1 mM; fresh medium without PQ was also added to control
untreated cells. 200 mM stock solution of PQ in phosphate
buffered saline (PBS) was prepared immediately before usage. In
case of B-lymphocytes that grow in suspension as aggregates, right
before PQ addition cell clumps were disaggregated by pipetting
and cells were seeded at a density of ,1.46105 cells per ml in a
desired volume. PQ was added to a final concentration of 1 mM.
In case of untreated control lymphocytes, PQ was omitted from
growth medium. Unless noted otherwise, PQ treatment continued
for 24 h, after which cells were collected for whole cell lysates/
total RNA preparation.
PQ treatment combined with transfection of minigenes was
done as follows. SH-SY5Y cells were plated at a density of
,2.86105 cells per one well of a 6-well plate. Next day the cells
were transfected with 1 mg of different minigenes using Lipofecta-
mine 2000 (Life Technologies) following the manufacturer’s
recommendations. Six hours after transfection cells were washed
once and conditioned medium harvested from growing SH-SY5Y
cells was added to the wells. Twelve hours post transfection, cells in
each well were trypsinized and collected in a total volume of 4 ml;
2.5 ml of this cell suspension were transferred to a new well of 6-
well plate and freshly prepared PQ was immediately added to a
final concentration of 1 mM (PQ treated cell), while 1.5 ml of this
suspension were plated in another well of 6-well plate and used as
an untreated control. Following 21 hours of PQ treatment, cells
were collected for total RNA preparation.
PQ treatment combined with transfection of ASOs was done as
follows. GM03813 primary fibroblasts were plated at a density of
,86105 cells per 100 mm tissue culture dish. Total number of six
dishes was seeded. Twenty-four hours later cells were transfected
with 50 nM of a given ASO (two plates were transfected with each
ASO) using Lipofectamine 2000 following the manufacturer’s
recommendations. Following another 24 hours the medium was
changed, and freshly prepared PQ was added to one of each pair
of transfected plates; the other plate served as a PQ untreated
control. PQ treatment continued for 24 hours, after what cell were
washed several times with ice-cold PBS and collected by scrapping.
For total RNA preparation ,1/4 of cells from each dish was used,
while 3/4 were used for making cell lysates.
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ASO Transfections
Delivery of ASOs into HeLa cells was done by reverse
transfection using Lipofectamine 2000. Complexes of Lipofecta-
mine 2000 and ASOs were prepared following the manufacturer’s
recommendations. The complexes were allowed to form for 20
minutes at room temperature, after what each complex (1 ml, in
Opti-MEM I Reduced Serum Medium) was mixed with 4 ml of
HeLa cell suspension in a 60 mm dish. Total number of HeLa
cells used for transfection varied from ,2.06106 to ,2.56106
cells. The final ASO concentration was 100 nM. Next day culture
medium was changed for the fresh one. About 38 hour post
transfection the cells were washed several times with ice-cold PBS
and collected by scraping. About 4/5th of cells were used for
making cell lysates, while 1/5th of cells were used for preparing
total RNA.
RT-PCR
For reverse transcription and PCR (RT-PCR), total RNA was
isolated using Trizol reagent (Life Technologies) following the
manufacturer’s recommendations. To generate cDNA, reverse
transcription was carried out using a SuperScript III reaction kit
(Life Technologies). For cDNA synthesis random primers
(Promega), an oligo(dT)12–18 primer (Life Technologies) or
gene-specific primer 39E8-Dde were employed. Generally, 0.5
to 1 mg of total RNA was used per 5 ml of Reverse transcriptase
(RTase) reaction. Minigene-specific spliced products were
amplified using Taq DNA polymerase and the following primer
combinations: P1 and P2 for SMNDI6 minigenes [68], P43 and
P45 for pTK vector-based minigenes, and P31 and 39Jun E8/
bb for minigenes with SMN promoters. For PCR amplification
of endogenous SMN the following pairs of primers were used:
either N-24 and P26 or P25 and P31 for exon 7 splicing [55];
59hSMN-E2b and P2–2 for MESDA. Of note, there were no
differences in endogenous SMN splicing pattern whether cDNA
produced with oligo(dT)12–18 or with a gene specific primer was
used for MESDA. PCR reactions were performed either in the
presence of a trace amount of [a-32P] dATP (3,000 Ci/mmole;
Perkin-Elmer Life Sciences) or with the 59-end-P32-labeled
primer, 59hSMN-E2b. End-labeling of 59hSMN-E2b was done
using c-ATP (3,000 Ci/mmole, Perkin-Elmer Life Sciences) and
T4 Polynucleotide Kinase (New England Biolabs). To distin-
guish splice isoforms originated from SMN2, PCR products
amplified with N-24 and P26 or P25 and P31 were subjected to
overnight DdeI digestion, followed by phenol:chloroform
extraction and ethanol precipitation [55]. In all cases PCR
products were resolved on a 6% native polyacrylamide gel.
Analysis and quantifications of splice products were performed
using a FPL-5000 Image Reader and Multi Gauge software
(Fuji Photo Film Inc). Results were confirmed by at least three
independent experiments. All primer sequences used in RT-
PCR are given in supporting data (Table S1).
Western Blot Analysis
Whole-cell extracts from HeLa, GM20384 and GM03813
were prepared using ice-cold RIPA buffer (Boston BioProducts)
supplemented with either Complete EDTA-free protease inhib-
itor cocktail (Roche Applied Science) or Halt Protease Inhibitor
Single-Use cocktail (Thermo Scientific). Protein concentrations
were determined using BCA protein assay kit (Thermo Scientif-
ic). Protein samples were resolved on an SDS-polyacrylamide gel
(11 or 12%) and transferred on polyvinylidene fluoride mem-
brane (Bio Trace PVDF, Pall Life Sciences). The following
primary and secondary antibodies were used: mouse monoclonal
anti-SMN (BD Transduction Laboratories), mouse monoclonal
anti-Gemin2 (Sigma-Aldrich), rabbit polyclonal anti-actin (Sig-
ma-Aldrich), horseradish-peroxidase-conjugated secondary anti-
bodies against mouse (Jackson ImmunoResearch) and rabbit (GE
Healthcare). After probing for SMN, membranes were stripped
(15 min at room temperature) using Restore Western Blot
Stripping Buffer (Thermo Scientific) and re-probed for b-actin.
Immunoreactive proteins were visualized with SuperSignal West
Dura Extended Duration Substrate or SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific). The mem-
branes were scanned using UVP BioSpectrum AC Imaging
System (UVP). Results were confirmed by at least three
independent experiments.
Statistical Analysis
All calculations were performed in Excel (Microsoft Office 2011
edition). Data were expressed as mean6standard error of the
mean (SEM). Statistical analyses were performed using the
unpaired Student’s t-test. Unless otherwise mentioned P values
were two-tailed and the level of statistical significance was set at
P,0.05.
Supporting Information
Figure S1 Distribution of splice forms revealed by
cloning and sequencing. A, Relative abundance of SMN
splice isoforms. All splice variants except D5,6 were cloned from
SH-SY5Y cells. Splice variant D5,6 was cloned from GM20383
cells. B, Evaluation of SMN splice isoforms generated under OS
caused by PQ treatment of SH-SY5Y cells. Cells were treated with
1 mM PQ for 24 hours and analyzed by RT-PCR, cloning and
sequencing.
(DOCX)
Figure S2 Pictogram showing relative abundance of
transcripts generated in various cell types undergoing
through OS. Peak values are derived from the band intensities in
lanes shown in Figure 4B. Pictograms were generated by
MultiGauge software version 3.0 (FUJIFILM). Abbreviation: FL,
Full-length transcript.
(DOCX)
Figure S3 Comparison of different splice variants in PQ
treated and untreated SH-SY5Y cells as determined by
qRT-PCR. A, Relative expression of splice isoforms from control
untreated and 1 mM PQ treated cells. qRT-PCR was performed
as described in Materials and Methods S1. Total SMN from
untreated SH-SY5Y was used for normalization. The values are
mean 6 SD. Abbreviations for transcripts: Total, total SMN; 7+,
exon 7-included; D7, exon 7 skipped; 5+, exon 5-included; D5,
exon 5 skipped; 3+, exon 3-included; D3, exon 3 skipped. *,
P,0.05; **, P,0.01. B, Log2 transformed fold changes in SMN
splice isoform levels between control untreated and 1 mM PQ
treated calculated based on the results shown in Panel (A). The
values are mean 6 SD. Abbreviations for transcripts: Total, total
SMN; 7+, exon 7-included; D7, exon 7 skipped; 5+, exon 5-
included; D5, exon 5 skipped; 3+, exon 3-included; D3, exon 3
skipped. *, P,0.05; **, P,0.01.
(DOCX)
Figure S4 Diagrammatic representation of minigenes
placed under the control of different promoters. A, SMN1
and SMN2 minigenes (pSMN1DI6 and pSMN2DI6) under the
control of CMV promoter. Cloning strategy is described earlier
[61]. B, SMN1 and SMN2 minigenes (pTK-SMN1DI6 and pTK-
SMN2DI6) under the control of TK promoter were generated by
subcloning into pTK-GLuc vector (New England Biolabs).
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Cloning strategy is described in Materials and methods. C, SMN1
and SMN2 minigenes (pWTP-SMN1DI6 and pWTP-SMN2DI6)
under the control of wild type SMN promoters were generated by
replacing CMV promoter with human SMN1 and SMN2
promoters, respectively. Cloning strategy is described in Materials
and Methods.
(DOCX)
Figure S5 Results showing specificity of 8-mer ASO
targeting GC-rich sequence. A, Diagrammatic representation
of the ASO target area as described in Figure 7A. B, Splicing
pattern of endogenous PLOD2 in SMA patient fibroblasts
transfected with different ASOs in the presence (+) or absence
(2) of PQ. Transfection, PQ treatment and RNA isolation
procedures were the same as described in Figure 7. PLOD2 spliced
products were analyzed by RT-PCR. RNA was converted to
cDNA using an oligo(dT)12–18 primer. PLOD2 transcripts were
amplified using E13-PLOD2 and E15-PLOD2 primers that
anneal to exons 13 and 15, respectively. Primer sequences are
given in Table S1.
(DOCX)
Table S1 List of primers used in this study.
(DOCX)
Materials and Methods S1 Detailed information on
methods used in this study.
(DOCX)
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